EA201591423A1 - Введение антитела к активину-а пациентам - Google Patents
Введение антитела к активину-а пациентамInfo
- Publication number
- EA201591423A1 EA201591423A1 EA201591423A EA201591423A EA201591423A1 EA 201591423 A1 EA201591423 A1 EA 201591423A1 EA 201591423 A EA201591423 A EA 201591423A EA 201591423 A EA201591423 A EA 201591423A EA 201591423 A1 EA201591423 A1 EA 201591423A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- activin
- subject
- antibodies
- compound
- activine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Reproductive Health (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Analytical Chemistry (AREA)
- Dermatology (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
Abstract
Настоящее изобретение относится к способам лечения рака яичника у субъекта путем введения субъекту при оценке уровней экспрессии субъектом специфических биомаркеров или ангиогенного соединения, относящегося к антителам к активину-А, такого как антитело к активину-А или активин-А-связывающий рецептор. В соответствии с некоторыми вариантами субъекту вводят по меньшей мере два соединения, при этом первое соединение представляет антитело к активину-А и второе соединение представляет собой химиотерапевтический агент, например капецитабин. Данное изобретение относится также к способам идентификации субъектов для лечения.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361759961P | 2013-02-01 | 2013-02-01 | |
US201361815220P | 2013-04-23 | 2013-04-23 | |
PCT/US2014/014490 WO2014121221A1 (en) | 2013-02-01 | 2014-02-03 | Administration of an anti-activin-a compound to a subject |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201591423A1 true EA201591423A1 (ru) | 2016-01-29 |
Family
ID=51263035
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201591423A EA201591423A1 (ru) | 2013-02-01 | 2014-02-03 | Введение антитела к активину-а пациентам |
Country Status (15)
Country | Link |
---|---|
US (3) | US20150359850A1 (ru) |
EP (2) | EP2951205B1 (ru) |
JP (1) | JP2016508504A (ru) |
KR (1) | KR20150136061A (ru) |
CN (1) | CN105431455A (ru) |
AU (1) | AU2014212014A1 (ru) |
CA (1) | CA2899889A1 (ru) |
CL (1) | CL2015002116A1 (ru) |
EA (1) | EA201591423A1 (ru) |
HK (1) | HK1218553A1 (ru) |
IL (1) | IL240139A0 (ru) |
MX (1) | MX2015009901A (ru) |
PH (1) | PH12015501709A1 (ru) |
SG (2) | SG11201505960VA (ru) |
WO (1) | WO2014121221A1 (ru) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2012339722B2 (en) | 2011-11-14 | 2017-09-14 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and/or Activin A |
SG11201505960VA (en) | 2013-02-01 | 2015-08-28 | Santa Maria Biotherapeutics Inc | Administration of an anti-activin-a compound to a subject |
TW201920262A (zh) | 2013-07-30 | 2019-06-01 | 美商再生元醫藥公司 | 抗活化素a之抗體及其用途 |
TW201625675A (zh) * | 2014-06-13 | 2016-07-16 | 聖塔瑪麗亞生物治療公司 | 經調配之受體多肽及相關方法 |
KR20180006386A (ko) * | 2015-04-22 | 2018-01-17 | 얼라이브젠 유에스에이 인코포레이티드 | 신규한 근육 소모 질환 치료용 하이브리드 actriib 리간드 트랩 단백질 |
CN109069467B (zh) * | 2015-11-11 | 2022-11-04 | 诺华股份有限公司 | 肌生成抑制蛋白拮抗剂的用途、含有它们的组合及其用途 |
PE20191741A1 (es) | 2017-04-05 | 2019-12-12 | Symphogen As | Terapias combinadas dirigidas a pd-1, tim-3, y lag-3 |
CN111787981A (zh) | 2018-03-01 | 2020-10-16 | 瑞泽恩制药公司 | 改变身体组成的方法 |
WO2024108158A1 (en) * | 2022-11-18 | 2024-05-23 | Byomass Inc. | Anti-activin a/b antibodies and uses thereof |
CN116948028B (zh) * | 2023-09-20 | 2023-11-28 | 北京合源汇丰医药科技有限公司 | 一种抗抑制素抗体及其应用 |
Family Cites Families (141)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US646A (en) | 1838-03-21 | Improvement in furnaces for smelting iron with anthracite | ||
US7947A (en) | 1851-02-25 | Bellows fob musical instruments | ||
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US4411993A (en) | 1981-04-29 | 1983-10-25 | Steven Gillis | Hybridoma antibody which inhibits interleukin 2 activity |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
USRE32011E (en) | 1981-12-14 | 1985-10-22 | Scripps Clinic And Research Foundation | Ultrapurification of factor VIII using monoclonal antibodies |
JPS58117537A (ja) | 1982-01-06 | 1983-07-13 | Toray Ind Inc | 感光性樹脂組成物 |
EP0088046B1 (de) | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipide in wässriger Phase |
US4737462A (en) | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
US4543439A (en) | 1982-12-13 | 1985-09-24 | Massachusetts Institute Of Technology | Production and use of monoclonal antibodies to phosphotyrosine-containing proteins |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
US4902614A (en) | 1984-12-03 | 1990-02-20 | Teijin Limited | Monoclonal antibody to human protein C |
US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4973577A (en) | 1986-04-04 | 1990-11-27 | The Salk Institute For Biological Studies | FSH-releasing peptides |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5011912A (en) | 1986-12-19 | 1991-04-30 | Immunex Corporation | Hybridoma and monoclonal antibody for use in an immunoaffinity purification system |
JPH01171495A (ja) | 1987-12-25 | 1989-07-06 | Ajinomoto Co Inc | モノクローナル抗体及びそれを用いる定量法 |
US5567584A (en) | 1988-01-22 | 1996-10-22 | Zymogenetics, Inc. | Methods of using biologically active dimerized polypeptide fusions to detect PDGF |
US5750375A (en) | 1988-01-22 | 1998-05-12 | Zymogenetics, Inc. | Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
WO1990014363A1 (en) | 1989-05-19 | 1990-11-29 | Amgen Inc. | Metalloproteinase inhibitor |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
JP3218637B2 (ja) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
EP0542810A1 (en) | 1990-08-02 | 1993-05-26 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
JP2958076B2 (ja) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
US20050186593A1 (en) | 1991-05-10 | 2005-08-25 | The Salk Institute For Biological Studies | Cloning and recombinant production of CRF receptor(s) |
US5885794A (en) | 1991-05-10 | 1999-03-23 | The Salk Institute For Biological Studies | Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily |
US6162896A (en) | 1991-05-10 | 2000-12-19 | The Salk Institute For Biological Studies | Recombinant vertebrate activin receptors |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
US5262522A (en) | 1991-11-22 | 1993-11-16 | Immunex Corporation | Receptor for oncostatin M and leukemia inhibitory factor |
JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化b−b10 |
US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
WO1993015722A1 (en) | 1992-02-07 | 1993-08-19 | Syntex (Usa) Inc. | Controlled delivery of pharmaceuticals from preformed porous microparticles |
US6153407A (en) | 1992-07-28 | 2000-11-28 | Beth Israel Deaconess Medical Center | Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics |
DK0672141T3 (da) | 1992-10-23 | 2003-06-10 | Immunex Corp | Fremgangsmåder til fremstilling af opløselige, oligomere proteiner |
DE69232604T2 (de) | 1992-11-04 | 2002-11-07 | City Of Hope Duarte | Antikörperkonstrukte |
GB9223377D0 (en) | 1992-11-04 | 1992-12-23 | Medarex Inc | Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes |
CA2157577C (en) | 1993-03-19 | 2009-11-17 | Se-Jin Lee | Growth differentiation factor-8 |
US5994618A (en) | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
US6465239B1 (en) | 1993-03-19 | 2002-10-15 | The John Hopkins University School Of Medicine | Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species |
US6607884B1 (en) | 1993-03-19 | 2003-08-19 | The Johns Hopkins University School Of Medicine | Methods of detecting growth differentiation factor-8 |
US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
DE69535641D1 (de) | 1994-04-29 | 2007-12-27 | Curis Inc | Morphogene protein-spezifische zelloberflächenrezeptoren und ihre verwendungen |
US5545616A (en) | 1994-09-22 | 1996-08-13 | Genentech, Inc. | Method for predicting and/or preventing preterm labor |
US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
US6133426A (en) | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
JP3614866B2 (ja) | 1997-06-12 | 2005-01-26 | リサーチ コーポレイション テクノロジーズ,インコーポレイティド | 人工抗体ポリペプチド |
US6891082B2 (en) | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
US6656475B1 (en) | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
US6472179B2 (en) | 1998-09-25 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
PT1129190E (pt) | 1998-11-13 | 2007-08-08 | Immunex Corp | Adn e polipéptidos de tslp humanos. |
DE60027135T2 (de) | 1999-01-21 | 2007-01-11 | Metamorphix, Inc. | Inhibitoren für wachstumdifferenzierungsfaktor und ihre anwendungen |
GB9928787D0 (en) | 1999-12-03 | 2000-02-02 | Medical Res Council | Direct screening method |
JP4487376B2 (ja) | 2000-03-31 | 2010-06-23 | 味の素株式会社 | 腎疾患治療剤 |
EP1290169A2 (en) | 2000-06-01 | 2003-03-12 | Amgen, Inc. | Cystine-knot polypeptides: cloaked-2 molecules and uses thereof |
US6812339B1 (en) | 2000-09-08 | 2004-11-02 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
GB0025144D0 (en) | 2000-10-13 | 2000-11-29 | Medical Res Council | Concatenated nucleic acid sequences |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
EP1539233B1 (en) | 2001-07-12 | 2011-04-27 | FOOTE, Jefferson | Super humanized antibodies |
AUPR638101A0 (en) | 2001-07-13 | 2001-08-09 | Bioa Pty Limited | Composition and method for treatment of disease |
EP1406929A2 (en) | 2001-07-18 | 2004-04-14 | MERCK PATENT GmbH | Glycoprotein vi fusion proteins |
US7737260B2 (en) | 2003-11-13 | 2010-06-15 | Hanmi Pharm. Co., Ltd | Protein complex using an immunoglobulin fragment and method for the preparation thereof |
GB0209896D0 (en) | 2002-04-30 | 2002-06-05 | Molmed Spa | Conjugate |
US20040223966A1 (en) | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
KR101304718B1 (ko) | 2002-12-20 | 2013-09-05 | 암겐 인코포레이티드 | 미오스타틴을 저해하는 결합제 |
US20040202995A1 (en) | 2003-04-09 | 2004-10-14 | Domantis | Nucleic acids, proteins, and screening methods |
UA85055C2 (ru) | 2003-06-02 | 2008-12-25 | Уайт | Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний |
PL3395338T3 (pl) | 2003-09-12 | 2019-10-31 | Amgen Inc | Szybko rozpuszczająca się formulacja zawierająca cynakalcet HCl |
US8110665B2 (en) | 2003-11-13 | 2012-02-07 | Hanmi Holdings Co., Ltd. | Pharmaceutical composition comprising an immunoglobulin FC region as a carrier |
WO2005051299A2 (en) | 2003-11-19 | 2005-06-09 | Dyax Corp. | Metalloproteinase-binding proteins |
CA2564538A1 (en) | 2004-04-22 | 2005-12-01 | Oregon Health And Science University | Compositions and methods for modulating signaling mediated by igf-1 receptor and erbb receptors |
ES2400687T3 (es) | 2004-04-23 | 2013-04-11 | Amgen Inc. | Formulaciones de liberación sostenida |
EP1740609A2 (en) | 2004-04-27 | 2007-01-10 | Research Development Foundation | Antagonism of tgf-beta superfamily receptor signaling |
CA2574777C (en) | 2004-07-23 | 2015-09-01 | Acceleron Pharma Inc. | Actrii receptor polypeptides, methods and compositions |
BRPI0514253A (pt) | 2004-08-12 | 2008-06-03 | Wyeth Corp | terapia de combinação para diabetes, obesidade e doenças cardiovasculares usando composições contendo inibidores de gdf-8 |
BRPI0516011A (pt) | 2004-09-24 | 2008-08-19 | Amgen Inc | moléculas fc modificadas |
CA2587903A1 (en) | 2004-11-17 | 2006-05-26 | Amgen Fremont Inc. | Fully human monoclonal antibodies to il-13 |
ES2395953T3 (es) | 2005-01-26 | 2013-02-18 | Amgen Fremont Inc. | Anticuerpos frente a interleucina-1 beta |
US20090238820A1 (en) | 2005-03-08 | 2009-09-24 | Allan Corey M | ANTI-MAdCAM ANTIBODY COMPOSITIONS |
KR100754667B1 (ko) | 2005-04-08 | 2007-09-03 | 한미약품 주식회사 | 비펩타이드성 중합체로 개질된 면역글로불린 Fc 단편 및이를 포함하는 약제학적 조성물 |
DOP2006000093A (es) | 2005-04-25 | 2007-01-31 | Pfizer | Anticuerpos contra miostatina |
PT2447283E (pt) * | 2005-09-07 | 2015-10-08 | Pfizer | Anticorpos monoclonais humanos para cinase-1 tipo recetor de activina (alk-1) |
US8067562B2 (en) | 2005-11-01 | 2011-11-29 | Amgen Inc. | Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 |
US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
CL2007002567A1 (es) * | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
CA2672758C (en) | 2006-12-18 | 2019-07-30 | Acceleron Pharma Inc. | Activin-actrii antagonists and uses for increasing red blood cell levels |
TW202021980A (zh) | 2007-02-02 | 2020-06-16 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
US8501678B2 (en) | 2007-03-06 | 2013-08-06 | Atara Biotherapeutics, Inc. | Variant activin receptor polypeptides and uses thereof |
TWI573802B (zh) | 2007-03-06 | 2017-03-11 | 安美基公司 | 變異之活動素受體多肽及其用途 |
EP2578684B1 (en) | 2007-03-19 | 2016-02-24 | National Research Council Of Canada | Antagonists of ligands and uses thereof |
CN103877564A (zh) * | 2007-09-18 | 2014-06-25 | 阿塞勒隆制药公司 | 活化素-actriia拮抗剂和减少或抑制fsh分泌的用途 |
EP2315602A4 (en) | 2008-06-26 | 2011-11-02 | Acceleron Pharma Inc | METHOD OF DOSING AN ACTRIIB ANTAGONIST AND MONITORING TREATED PATIENTS |
TW201919685A (zh) | 2008-08-14 | 2019-06-01 | 美商艾瑟勒朗法瑪公司 | 使用gdf阱以增加紅血球水平 |
US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
BRPI0920962A2 (pt) * | 2008-11-26 | 2016-07-12 | Amgen Inc | variantes de polipeptídeos receptores de activina iib e usos dos mesmos |
CA2749544A1 (en) | 2009-01-13 | 2010-07-22 | Acceleron Pharma Inc. | Methods for increasing adiponectin |
MA33279B1 (fr) | 2009-04-27 | 2012-05-02 | Novartis Ag | Compositions et procédés pour l'augmentation de la croissance des muscles |
CA2764890A1 (en) | 2009-06-08 | 2010-12-16 | Acceleron Pharma Inc. | Methods for increasing thermogenic adipocytes |
WO2011031901A1 (en) | 2009-09-09 | 2011-03-17 | Acceleron Pharma Inc. | Actriib antagonists and dosing and uses thereof |
WO2011085165A2 (en) * | 2010-01-08 | 2011-07-14 | The Brigham And Women's Hospital, Inc. | Ca-125 immune complexes as biomarkers of ovarian cancer |
WO2011123691A1 (en) * | 2010-03-31 | 2011-10-06 | Keryx Biopharmaceuticals, Inc. | Perifosine and capecitabine as a combined treatment for cancer |
WO2012064771A1 (en) * | 2010-11-08 | 2012-05-18 | Acceleron Pharma, Inc. | Actriia binding agents and uses thereof |
EP2793925B1 (en) * | 2011-12-19 | 2019-03-20 | Amgen Inc. | Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof |
WO2013106715A1 (en) * | 2012-01-13 | 2013-07-18 | Allergan, Inc. | Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation |
US9401875B2 (en) | 2012-06-01 | 2016-07-26 | Nippon Telegraph And Telephone Corporation | Packet transfer processing method and packet transfer processing device |
SG11201505960VA (en) | 2013-02-01 | 2015-08-28 | Santa Maria Biotherapeutics Inc | Administration of an anti-activin-a compound to a subject |
US20140220033A1 (en) | 2013-02-01 | 2014-08-07 | Santa Maria Biotherapeutics, Inc. | Administration of an Anti-Activin-A Compound to a Subject |
EP3094751A4 (en) | 2014-01-14 | 2017-06-07 | Santa Maria Biotherapeutics, Inc. | Activin inhibitor response prediction and uses for treatment |
US9300829B2 (en) | 2014-04-04 | 2016-03-29 | Canon Kabushiki Kaisha | Image reading apparatus and correction method thereof |
TW201625675A (zh) | 2014-06-13 | 2016-07-16 | 聖塔瑪麗亞生物治療公司 | 經調配之受體多肽及相關方法 |
-
2014
- 2014-02-03 SG SG11201505960VA patent/SG11201505960VA/en unknown
- 2014-02-03 EA EA201591423A patent/EA201591423A1/ru unknown
- 2014-02-03 CA CA2899889A patent/CA2899889A1/en not_active Abandoned
- 2014-02-03 CN CN201480020307.6A patent/CN105431455A/zh active Pending
- 2014-02-03 US US14/764,288 patent/US20150359850A1/en not_active Abandoned
- 2014-02-03 JP JP2015556210A patent/JP2016508504A/ja active Pending
- 2014-02-03 AU AU2014212014A patent/AU2014212014A1/en not_active Abandoned
- 2014-02-03 KR KR1020157023772A patent/KR20150136061A/ko not_active Application Discontinuation
- 2014-02-03 EP EP14746114.9A patent/EP2951205B1/en active Active
- 2014-02-03 EP EP21190424.8A patent/EP3985024A1/en active Pending
- 2014-02-03 MX MX2015009901A patent/MX2015009901A/es unknown
- 2014-02-03 WO PCT/US2014/014490 patent/WO2014121221A1/en active Application Filing
- 2014-02-03 SG SG10201706148WA patent/SG10201706148WA/en unknown
-
2015
- 2015-07-23 IL IL240139A patent/IL240139A0/en unknown
- 2015-07-29 CL CL2015002116A patent/CL2015002116A1/es unknown
- 2015-07-31 PH PH12015501709A patent/PH12015501709A1/en unknown
-
2016
- 2016-06-06 HK HK16106466.4A patent/HK1218553A1/zh unknown
-
2019
- 2019-12-13 US US16/714,407 patent/US11541070B2/en active Active
-
2022
- 2022-12-22 US US18/087,345 patent/US20230201231A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN105431455A (zh) | 2016-03-23 |
HK1218553A1 (zh) | 2017-02-24 |
US20200108085A1 (en) | 2020-04-09 |
AU2014212014A1 (en) | 2015-08-27 |
JP2016508504A (ja) | 2016-03-22 |
WO2014121221A8 (en) | 2015-12-23 |
SG11201505960VA (en) | 2015-08-28 |
EP3985024A1 (en) | 2022-04-20 |
US20150359850A1 (en) | 2015-12-17 |
SG10201706148WA (en) | 2017-08-30 |
WO2014121221A1 (en) | 2014-08-07 |
CL2015002116A1 (es) | 2016-05-27 |
EP2951205B1 (en) | 2021-08-11 |
MX2015009901A (es) | 2016-04-06 |
US11541070B2 (en) | 2023-01-03 |
US20230201231A1 (en) | 2023-06-29 |
IL240139A0 (en) | 2015-09-24 |
CA2899889A1 (en) | 2014-08-07 |
EP2951205A4 (en) | 2016-09-07 |
KR20150136061A (ko) | 2015-12-04 |
EP2951205A1 (en) | 2015-12-09 |
PH12015501709A1 (en) | 2015-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201591423A1 (ru) | Введение антитела к активину-а пациентам | |
UA118453C2 (uk) | Спосіб лікування пухлин у пацієнта | |
EA201891983A1 (ru) | Комбинированная терапия антителами к cd73 | |
EA201792451A1 (ru) | Антитела к ox40 и способы их применения | |
EA201691438A1 (ru) | Антитело, которое связывается с erbb-2 и erbb-3 | |
EA201890131A1 (ru) | Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38 | |
EA202190485A1 (ru) | Соединения, модулирующие fxr (nr1h4) | |
EA201691323A1 (ru) | Анти-vista антитела и фрагменты | |
EA201590671A1 (ru) | Комбинация антител к kir и антител к pd-1 для лечения злокачественной опухоли | |
EA201690617A1 (ru) | Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей | |
EA201890513A1 (ru) | Антитела к bcma, биспецифические антигенсвязывающие молекулы, которые связываются с bcma и cd3, и их применение | |
EA201691487A1 (ru) | Антитела человека к pd-l1 | |
EA201790530A1 (ru) | Агенты, связывающиеся с cd123, и виды их применения | |
EA201501032A1 (ru) | Фармацевтическая композиция, способы лечения и ее применения | |
EA201492137A1 (ru) | Антитела к cd33 и их применение в лечении рака | |
EA201491541A1 (ru) | АНТИТЕЛА ПРОТИВ ИНТЕГРИНОВ αvβ6 И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННЫХ НОВООБРАЗОВАНИЙ | |
UA114891C2 (uk) | ІЗОЛЬОВАНЕ АНТИТІЛО ЛЮДИНИ, ЯКЕ СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З АНГІОПОЕТИНПОДІБНИМ БІЛКОМ 3 ЛЮДИНИ (hАNGPTL3), ТА ЙОГО ЗАСТОСУВАННЯ | |
UA116873C2 (uk) | Антитіло, яке зв'язується з ox40 | |
EA201991704A2 (ru) | Моноклональные антитела против ингибитора пути тканевого фактора (tfpi) | |
EA201791203A1 (ru) | ЛЕКАРСТВЕННЫЙ КОНЪЮГАТ АНТИТЕЛА ПРОТИВ с-МЕТ | |
MX2020009879A (es) | Anticuerpos anti-il-27 y sus usos. | |
EA202191666A1 (ru) | Антитела к il-27 и их применение | |
NZ715177A (en) | Anti-vegf antibody, and pharmaceutical composition for preventing, diagnosing or treating cancer or angiogenesis-related diseases, containing same | |
EA201691020A1 (ru) | Способы лечения и предотвращения вызываемой аллогенными антителами хронической болезни "трансплантат против хозяина" | |
BR112018073945A2 (pt) | métodos para tratamento de miastenia grave generalizada refratária |